Detalhe da pesquisa
1.
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.
Blood
; 137(26): 3616-3628, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33763699
2.
Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR.
Blood
; 133(2): 147-155, 2019 01 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30478094
3.
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
N Engl J Med
; 371(10): 906-17, 2014 Sep 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-25184863
4.
Safety and efficacy of targeted-dose busulfan and bortezomib as a conditioning regimen for patients with relapsed multiple myeloma undergoing a second autologous blood progenitor cell transplantation.
Biol Blood Marrow Transplant
; 20(12): 1949-57, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25139216
5.
Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study.
Leukemia
; 34(7): 1875-1884, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32001798
6.
Health related quality of life for multiple myeloma patients according to treatment strategy after autologous stem cell transplant: a cross-sectional study using EORTC, EQ-5D and MY-20 scales.
Leuk Lymphoma
; 60(5): 1275-1282, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30380358
7.
Prolonged progression-free survival and preserved quality of life in the Canadian prospective study of tositumomab and iodine(131)-tositumomab for previously treated, rituximab-exposed, indolent non-Hodgkin lymphoma.
Leuk Lymphoma
; 55(12): 2754-60, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24528219
8.
Lenalidomide plus melphalan without prednisone for previously untreated older patients with multiple myeloma: a phase II trial.
Clin Lymphoma Myeloma Leuk
; 13(1): 19-24, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23141150